NO844489L - Fremgangsmaate ved fremstilling av nye atriale peptider - Google Patents

Fremgangsmaate ved fremstilling av nye atriale peptider

Info

Publication number: NO844489L
Authority: NO; Norway
Prior art keywords: ser; peptide; arg; production; phe
Prior art date: 1983-11-10

Application number

NO844489A

Other languages

English (en)

Norwegian (no)

Inventor

Philip Needleman

Original Assignee

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-11-10

Filing date

1984-11-09

Publication date

1985-05-13

1984-11-09 Application filed by Univ Washington filed Critical Univ Washington

1985-05-13 Publication of NO844489L publication Critical patent/NO844489L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 71
238000000034 method Methods 0.000 title claims description 21
230000001746 atrial effect Effects 0.000 title claims description 12
102000004196 processed proteins & peptides Human genes 0.000 title description 34
238000002360 preparation method Methods 0.000 title description 6
108010082685 antiarrhythmic peptide Proteins 0.000 claims description 21
230000001452 natriuretic effect Effects 0.000 claims description 19
238000004128 high performance liquid chromatography Methods 0.000 claims description 17
229920005654 Sephadex Polymers 0.000 claims description 13
239000012507 Sephadex™ Substances 0.000 claims description 13
YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 claims description 12
102000004169 proteins and genes Human genes 0.000 claims description 12
108090000623 proteins and genes Proteins 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 11
239000011347 resin Substances 0.000 claims description 11
229920005989 resin Polymers 0.000 claims description 11
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 11
125000003275 alpha amino acid group Chemical group 0.000 claims description 9
239000006228 supernatant Substances 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
238000009835 boiling Methods 0.000 claims description 6
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims description 5
238000005119 centrifugation Methods 0.000 claims description 5
238000004255 ion exchange chromatography Methods 0.000 claims description 5
JAWGSPUJAXYXJA-IHRRRGAJSA-N Ser-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=CC=C1 JAWGSPUJAXYXJA-IHRRRGAJSA-N 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
238000011033 desalting Methods 0.000 claims description 4
238000001641 gel filtration chromatography Methods 0.000 claims description 4
JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical group CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
238000011084 recovery Methods 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
229940024606 amino acid Drugs 0.000 description 28
235000001014 amino acid Nutrition 0.000 description 26
241000700159 Rattus Species 0.000 description 24
230000000968 intestinal effect Effects 0.000 description 22
150000001413 amino acids Chemical class 0.000 description 20
239000002934 diuretic Substances 0.000 description 20
238000012360 testing method Methods 0.000 description 20
241000283973 Oryctolagus cuniculus Species 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
229950008486 carperitide Drugs 0.000 description 18
230000000694 effects Effects 0.000 description 17
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
241000287828 Gallus gallus Species 0.000 description 15
102000002723 Atrial Natriuretic Factor Human genes 0.000 description 14
101800001288 Atrial natriuretic factor Proteins 0.000 description 14
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 13
238000001727 in vivo Methods 0.000 description 12
238000000746 purification Methods 0.000 description 12
102400001275 Atriopeptin-2 Human genes 0.000 description 11
108010034703 atrial natriuretic factor prohormone (103-125) Proteins 0.000 description 11
XXPVSJGWOXCVLF-VSJANKAZSA-N atriopeptin ii Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)[C@@H](C)CC)C1=CC=CC=C1 XXPVSJGWOXCVLF-VSJANKAZSA-N 0.000 description 11
230000004071 biological effect Effects 0.000 description 11
210000002700 urine Anatomy 0.000 description 11
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
102400001287 Atriopeptin-1 Human genes 0.000 description 10
108010033590 atrial natriuretic factor prohormone (103-123) Proteins 0.000 description 10
210000002460 smooth muscle Anatomy 0.000 description 10
239000000050 smooth muscle relaxant Substances 0.000 description 10
AYCBRUDZNRVKGK-GWLSAQFNSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)[C@@H](C)CC)C1=CC=CC=C1 AYCBRUDZNRVKGK-GWLSAQFNSA-N 0.000 description 9
102400001276 Atriopeptin-3 Human genes 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 9
108010034646 atrial natriuretic factor prohormone (103-126) Proteins 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
239000005695 Ammonium acetate Substances 0.000 description 8
101500027369 Rattus norvegicus Atriopeptin-3 Proteins 0.000 description 8
229940043376 ammonium acetate Drugs 0.000 description 8
235000019257 ammonium acetate Nutrition 0.000 description 8
210000002464 muscle smooth vascular Anatomy 0.000 description 8
230000003389 potentiating effect Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
210000000664 rectum Anatomy 0.000 description 8
230000002792 vascular Effects 0.000 description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
210000000709 aorta Anatomy 0.000 description 7
239000000284 extract Substances 0.000 description 7
229910052708 sodium Inorganic materials 0.000 description 7
239000011734 sodium Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000002249 anxiolytic agent Substances 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
210000002837 heart atrium Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
239000012071 phase Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
-1 Phenylthiohydantoin amino acids Chemical class 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
239000000812 cholinergic antagonist Substances 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
230000001882 diuretic effect Effects 0.000 description 5
239000007789 gas Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
229960004452 methionine Drugs 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 5
230000002048 spasmolytic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000282465 Canis Species 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
229940039009 isoproterenol Drugs 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
108010018625 phenylalanylarginine Proteins 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000008327 renal blood flow Effects 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000010532 solid phase synthesis reaction Methods 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000011067 equilibration Methods 0.000 description 3
230000029142 excretion Effects 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
238000000819 phase cycle Methods 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000011148 porous material Substances 0.000 description 3
238000011002 quantification Methods 0.000 description 3
230000002040 relaxant effect Effects 0.000 description 3
229940124550 renal vasodilator Drugs 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
235000004400 serine Nutrition 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
230000002883 vasorelaxation effect Effects 0.000 description 3
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 2
101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
108020001621 Natriuretic Peptide Proteins 0.000 description 2
102000004571 Natriuretic peptide Human genes 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
IWRZUGHCHFZYQZ-UFYCRDLUSA-N Phe-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 IWRZUGHCHFZYQZ-UFYCRDLUSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
101500027368 Rattus norvegicus Atriopeptin-2 Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
229960004484 carbachol Drugs 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000035619 diuresis Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000005048 flame photometry Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000000692 natriuretic peptide Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000004648 relaxation of smooth muscle Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
229960001153 serine Drugs 0.000 description 2
229920000260 silastic Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000005303 weighing Methods 0.000 description 2
DMBKPDOAQVGTST-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-LBPRGKRZSA-N 0.000 description 1
SOHLZANWVLCPHK-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(=O)OCC1=CC=CC=C1 SOHLZANWVLCPHK-LBPRGKRZSA-N 0.000 description 1
CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 1
QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical group CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101000757797 Geobacillus stearothermophilus Aminopeptidase 2 Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 1
MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
101000733766 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Aminopeptidase 2, mitochondrial Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000012539 chromatography resin Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000000674 effect on sodium Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
239000002833 natriuretic agent Substances 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO844489A 1983-11-10 1984-11-09 Fremgangsmaate ved fremstilling av nye atriale peptider NO844489L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55137283A	1983-11-10	1983-11-10
US06/569,684 US4496544A (en)	1983-11-10	1984-01-10	Atrial Peptides

Publications (1)

Publication Number	Publication Date
NO844489L true NO844489L (no)	1985-05-13

Family

ID=27069747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO844489A NO844489L (no)	1983-11-10	1984-11-09	Fremgangsmaate ved fremstilling av nye atriale peptider

Country Status (12)

Country	Link
US (1)	US4496544A (ja)
EP (1)	EP0142487B1 (ja)
JP (1)	JPH0672156B2 (ja)
AU (1)	AU566235B2 (ja)
DE (1)	DE3480930D1 (ja)
DK (1)	DK533484A (ja)
ES (1)	ES8606390A1 (ja)
FI (1)	FI83661C (ja)
GR (1)	GR80905B (ja)
IE (1)	IE58819B1 (ja)
IL (1)	IL73466A (ja)
NO (1)	NO844489L (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0116784B1 (en) *	1982-02-22	1992-06-10	Queen's University At Kingston	Atrial natriuretic factor
AU572173B2 (en) *	1983-08-29	1988-05-05	Institut De Recherches Cliniques De Montreal	Natriuretic factors
JPS60136596A (ja) *	1983-12-26	1985-07-20	Suntory Ltd	ペプチド及びこれを有効成分とする利尿剤
US4952561A (en) *	1984-02-07	1990-08-28	Merck & Co., Inc.	Cardiac atrial peptides
JPH0794473B2 (ja) *	1984-03-02	1995-10-11	サントリー株式会社	新規なペプチド及びこれを有効成分とする利尿剤
US5212286A (en) *	1984-04-19	1993-05-18	Scios Nova Inc.	Atrial natriuretic/vasodilator peptide compounds
DE3588006T2 (de) *	1984-04-19	1995-08-10	Scios Nova Inc	Atrielle natriumuretische/gefässerweiterende polypeptide.
US4618600A (en) *	1984-04-19	1986-10-21	Biotechnology Research Associates, J.V.	Novel polypeptide diuretic/vasodilators
WO1985004872A1 (en) *	1984-04-24	1985-11-07	The Salk Institute For Biological Studies	Atrial peptide analogs
JPH0672157B2 (ja) *	1984-08-29	1994-09-14	味の素株式会社	新規ペプチド
US4652549A (en) *	1985-01-22	1987-03-24	Merck & Co., Inc.	Cardiac anti-hypertrophic agents
US5087564A (en) *	1985-06-20	1992-02-11	Monsanto Company	Release of recombinant peptides from polypeptides using V8 endopeptidase
FI872959A7 (fi) *	1985-11-05	1987-07-03	California Biotechnology Inc	Natriureettisen vaikutuksen omaavien sydämen eteispeptidien analogeja .
JP3042782B2 (ja) *	1985-11-05	2000-05-22	サイオスインコーポレイテッド	心房性ナトリウム尿排泄亢進ペプチド類似化合物
US4757048A (en) *	1985-11-05	1988-07-12	Biotechnology Research Associates J.V.	Synthetic analogs of atrial natriuretic peptides
DE3614833A1 (de) *	1986-01-16	1987-07-23	Hoechst Ag	Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US4716147A (en) *	1986-03-27	1987-12-29	Monsanto Company	Synthetic airial peptides
US4721704A (en) *	1986-05-09	1988-01-26	Peninsula Laboratories, Inc.	Potent synthetic atrial peptide analogs
EP0246795A3 (en) *	1986-05-20	1990-04-04	Advanced Peptide Development Limited	Synthetic natriuretic peptides
US4740499A (en) *	1986-07-28	1988-04-26	Monsanto Company	Method of enhancing the bioactivity of atrial peptides
US5565606A (en) *	1986-10-21	1996-10-15	Hoechst Aktiengesellschaft	Synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method
DE3723551A1 (de) *	1987-07-16	1989-01-26	Hoechst Ag	Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US4804650A (en) *	1986-10-28	1989-02-14	Biotechnology Research Associates, J.V.	Analogs of atrial natriuretic peptides
US5500230A (en) *	1987-01-23	1996-03-19	The General Hospital Corporation	Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
EP0583821B1 (en) *	1987-01-23	2000-03-29	The General Hospital Corporation	Hydralazine as topical treatment for glaucoma
IT1216865B (it)	1987-02-03	1990-03-14	Eniricerche Spa	Derivato argininico, procedimento per la sua preparazione e suo impiego nelle sintesi peptidiche.
DE3881467T2 (de) *	1987-10-09	1993-10-21	Agency Ind Science Techn	Vasokonstriktor-Peptid.
US4935492A (en) *	1987-12-24	1990-06-19	California Biotechnology Inc.	Cyclic analogs of atrial natriuretic peptides
US5047397A (en) *	1988-08-26	1991-09-10	California Biotechnology Inc.	Linear analogs of atrial natriuretic peptides
US5114923A (en) *	1988-05-31	1992-05-19	California Biotechnology Inc.	Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) *	1988-05-31	1997-08-05	John Lewicki	Recombinant techniques for production of novel natriuretic and vasodilator peptides
JP2801079B2 (ja) *	1990-11-14	1998-09-21	サントリー株式会社	Ａｎｐ関連新規ペプチド
JP2809533B2 (ja) *	1991-01-31	1998-10-08	壽之松尾	Ｃｎｐ類似体ペプチド
US6525022B1 (en)	1993-11-12	2003-02-25	Genentech, Inc.	Receptor specific atrial natriuretic peptides
US5846932A (en) *	1993-11-12	1998-12-08	Genentech, Inc.	Receptor specific atrial natriuretic peptides
US5665704A (en) *	1993-11-12	1997-09-09	Genentech, Inc.	Receptor specific atrial natriuretic peptides
US5486519A (en) *	1994-08-22	1996-01-23	Greenwald; James E.	Method for treatment of acute renal failure
US5521191A (en) *	1994-10-17	1996-05-28	Washington University	Method for treatment of arterial stenosis
US20060177870A1 (en) *	2003-04-28	2006-08-10	Ciphergen Biosystems, Inc	Immunoassays
WO2005000095A2 (en) *	2003-06-20	2005-01-06	Mayo Foundation For Medical Education And Research	Isoforms of brain natriuretic peptide
EP2004633A4 (en) *	2006-03-30	2009-08-26	Palatin Technologies Inc	LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
CA2647143A1 (en) *	2006-03-30	2007-10-11	Palatin Technologies, Inc.	Cyclic natriuretic peptide constructs
US8580746B2 (en)	2006-03-30	2013-11-12	Palatin Technologies, Inc.	Amide linkage cyclic natriuretic peptide constructs
CN101501067B (zh) *	2006-08-08	2013-01-16	梅约医学教育与研究基金会	利尿和利尿钠的多肽
WO2009036448A2 (en) *	2007-09-15	2009-03-19	Mayo Foundation For Medical Education And Research	Natriuretic peptide receptor-c agonists
CN103906761B (zh)	2011-08-30	2016-12-21	梅约医学教育与研究基金会	利钠多肽
WO2013103896A1 (en)	2012-01-06	2013-07-11	Mayo Foundation For Medical Education And Research	Treating cardiovascular or renal diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA846084B (en) *	1983-08-29	1985-05-29	Montreal Inst Rech Cliniques	Natriuretic factors

1984
- 1984-01-10 US US06/569,684 patent/US4496544A/en not_active Expired - Lifetime
- 1984-11-08 ES ES537520A patent/ES8606390A1/es not_active Expired
- 1984-11-09 IE IE288184A patent/IE58819B1/en not_active IP Right Cessation
- 1984-11-09 GR GR80905A patent/GR80905B/el unknown
- 1984-11-09 JP JP59236542A patent/JPH0672156B2/ja not_active Expired - Lifetime
- 1984-11-09 DK DK533484A patent/DK533484A/da not_active Application Discontinuation
- 1984-11-09 NO NO844489A patent/NO844489L/no unknown
- 1984-11-09 DE DE8484870149T patent/DE3480930D1/de not_active Expired - Lifetime
- 1984-11-09 AU AU35252/84A patent/AU566235B2/en not_active Ceased
- 1984-11-09 EP EP84870149A patent/EP0142487B1/en not_active Expired - Lifetime
- 1984-11-09 IL IL73466A patent/IL73466A/xx not_active IP Right Cessation
- 1984-11-09 FI FI844424A patent/FI83661C/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0142487B1 (en)	1990-01-03
FI83661B (fi)	1991-04-30
DK533484A (da)	1985-05-11
FI83661C (fi)	1991-08-12
US4496544A (en)	1985-01-29
IE842881L (en)	1985-05-10
AU566235B2 (en)	1987-10-15
IL73466A0 (en)	1985-02-28
EP0142487A3 (en)	1986-04-30
ES8606390A1 (es)	1986-04-01
AU3525284A (en)	1985-05-16
FI844424A0 (fi)	1984-11-09
EP0142487A2 (en)	1985-05-22
DE3480930D1 (de)	1990-02-08
FI844424L (fi)	1985-05-11
JPS60214797A (ja)	1985-10-28
GR80905B (en)	1985-04-02
IE58819B1 (en)	1993-11-17
ES537520A0 (es)	1986-04-01
JPH0672156B2 (ja)	1994-09-14
DK533484D0 (da)	1984-11-09
IL73466A (en)	1989-03-31

Publication	Publication Date	Title
NO844489L (no)	1985-05-13	Fremgangsmaate ved fremstilling av nye atriale peptider
Kangawa et al.	1985	Structural identification of β-and γ-human atrial natriuretic polypeptides
Sudoh et al.	1988	Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain
US4508712A (en)	1985-04-02	Atrial peptide
Kangawa et al.	1984	Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)
Forssmann et al.	1984	The auricular myocardiocytes of the heart constitute an endocrine organ characterization of a porcine cardiac peptide hormone, cardiodilatin-126
DK2402369T3 (en)	2016-02-01	Peptide fragments for inducing synthesis of extracellular matrix proteins
US4935492A (en)	1990-06-19	Cyclic analogs of atrial natriuretic peptides
St-Pierre et al.	1981	Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogs
EP0289287A2 (en)	1988-11-02	Amyloid peptides
US20030171536A1 (en)	2003-09-11	Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
US5336759A (en)	1994-08-09	Biologically active peptide derived from frog (frog CNP)
WO1994020534A1 (en)	1994-09-15	Vasonatrin peptide and analogs thereof
JPH06500311A (ja)	1994-01-13	ヒスチジン置換されたヒト成長ホルモン放出因子類縁体
AU614738B2 (en)	1991-09-12	New cardiodilatin fragment, process for preparing same and use thereof
DE3782073T2 (de)	1993-05-06	Synthetische atriale peptide.
US4557864A (en)	1985-12-10	Atrial peptides
JP2002511067A (ja)	2002-04-09	環式ｃｒｆアゴニスト
Zhang et al.	2010	Role of the intra-A-chain disulfide bond of insulin-like peptide 3 in binding and activation of its receptor, RXFP2
Takei et al.	1994	Eel ventricular natriuretic peptide: isolation of a low molecular size form and characterization of plasma form by homologous radioimmunoassay
US4732972A (en)	1988-03-22	Polypeptides having growth hormone releasing activity
US5262521A (en)	1993-11-16	Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof
JP3042782B2 (ja)	2000-05-22	心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH02223593A (ja)	1990-09-05	ヒトカルパスタチン様ポリペプチド
JPH04321699A (ja)	1992-11-11	新規な利尿ペプチド